Changes in mononuclear cell subsets in capillary and venous blood of patients with psoriasis depending on the treatment

Cover Page

Cite item

Full Text

Abstract

Topical glucocorticoids are conventionally used to treat psoriasis, but such treatment provides a short-term effect, and may cause various complications during long-term usage. A detailed study of the immunopathogenesis of psoriasis has made it possible to use bioengineered drugs that block the main cytokines. It has been shown that IL-36 plays an important regulatory role in pathogenesis of psoriasis. The aim of the study was to study therapeutic effect of patients with psoriasis using topical glucocorticoid hormone versus IL- 36 receptor antagonist (RAIL-36), with respect to clinical course of psoriasis and the subsets of mononuclear cells in venous and capillary blood taken close to the focus of inflammation. 16 patients with psoriasis (group 1a) received 0.1% mometasone cream for 14 days; 20 patients of group 1b received a gel containing 0.4% recombinant RAIL-36 for 14 days. Control group included 20 healthy adults. Treatment efficacy was assessed by PASI, DISHS and DLQI indices. 19 lymphocyte subsets and 3 monocyte subsets were assessed by four-color staining of whole capillary and venous blood with erythrocyte lysis using BD Biosciences (USA) technologies and reagents. It was shown that both drugs led to a decrease in the severity of the disease at the end of treatment. However, 2 weeks after the end of treatment in group 1a, the disease indexes nearly returned to the initial values. Meanwhile, the reduced index levels persisted 2 weeks later in group 1b. Significant deviations (more pronounced in capillary blood) were revealed for the levels of several leukocyte subsets in the psoriasis patients compared with healthy persons. As a result of treatment, we have revealed some changes in the levels of leukocyte subsets common to the two groups, and special differences for the two treatment options, that were more pronounced in capillary blood samples. Both medical preparations used are suitable for treatment of psoriasis.

About the authors

S. V. Sennikova

G. Gabrichevsky Research Institute for Epidemiology and Microbiology

Email: toptyginaanna@rambler.ru

Postgraduate Student, Laboratory of Cytokines

Russian Federation, Moscow

A. P. Toptygina

G. Gabrichevsky Research Institute for Epidemiology and Microbiology; Lomonosov Moscow State University

Author for correspondence.
Email: toptyginaanna@rambler.ru

PhD, MD (Medicine), Chief Research Associate, Head, Laboratory of Cytokines; Professor, Department of Immunology, Faculty of Biology

Russian Federation, Moscow; Moscow

References

  1. Колобов А.А., Кондратьева Е.В., Кудлинг Т.В., Карасев М.М., Калинин Р.С., Протасов Е.А., Нимирицкий П.П., Стефанов В.Е., Александров Г.В., Петров А.В., Симбирцев А.С. Разработка препарата для лечения псориаза на основе рекомбинантного рецепторного антагониста интерлейкина-36 (IL-36RA) человека //Медицинская иммунология, 2017. Т. 19, № S. С. 271. [Kolobov A.A., Kondratieva E.V., Kudling T.V., Karasev M.M., Kalinin R.S., Protasov E.A., Nimiritsky P.P., Stefanov V.E., Aleksandrov G.V., Petrov A.V., Simbirtsev A.S. Development of a drug for the treatment of psoriasis based on the recombinant human interleukin-36 receptor antagonist (IL-36RA). Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, No. S, p. 271. (In Russ.)] doi: 10.15789/1563-0625-2017-0.
  2. Олисова О.Ю., Анпилогова Е.М. Системная терапия псориаза: от метотрексата до генно-инженерных биологических препаратов // Вестник дерматологии и венерологии, 2020. Т. 96, № 3. С. 7-26. [Olisova O. Yu., Anpilogova E.M. Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik dermatologii i venerologii = Journal of Dermatology and Venereology, 2020, Vol. 96, no. 3, pp. 7-26. (In Russ.)]
  3. Сенникова С.В., Топтыгина А.П., Семикина Е.Л., Закиров Р.Ш., Акулова С.С. Субпопуляционный состав мононуклеаров и цитокиновый профиль венозной и капиллярной крови больных псориазом и здоровых людей // Медицинская иммунология, 2021. Т. 23, № 6. С. 1333-1346. [Sennikova S.V., Toptygina A.P., Semikina E.L., Zakirov R.Sh., Akulova S.S. Mononuclear subsets and cytokine profile of venous and capillary blood in patients with psoriasis and healthy people. Meditsinskaya immunologiya = Medical Immunology (Russia) , 2021, Vol. 23, no. 6, pp. 1333-1346. (In Russ.)] doi: 10.15789/1563-0625-MSA-2391.
  4. Bachelez H., Choon S.E., Marrakchi S., Burden A.D., Tsai T.F., Morita A., Turki H., Hall D.B., Shear M., Baum P., Padula S.J., Thoma C. Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med., 2019, Vol. 380, no. 10, pp. 981-983.
  5. Boehncke W.H., Brembilla N.C. Autoreactive T-lymphocytes in inflammatory skin diseases. Front. Immunol., 2019, Vol. 10, 1198. doi: 10.3389/fimmu.2019.01198.
  6. Boutet M.-A., Bart G., Penhoat M., Amiaud J., Brulin B., Charrier C., Morel F., Lecon J.C., Rolli-Derkinderen M., Bourreille A., Vigne S., Gabay C., Palmer G., Le Goff B., Blanchard F. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol., 2016, Vol. 184, pp. 159-173.
  7. Ceccarelli M., Venanzi Rullo E., Berretta M., Cacopardo B., Pellicanò G.F., Nunnari G., Guarneri C. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. Dermatol. Ther., 2021, Vol. 34, no. 1, e14660. doi: 10.1111/dth.14660.
  8. Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci., 2018, Vol. 19, 179. doi: 10.3390/ijms19010179.
  9. D’Erme A.M., Wilsmann-Theis D., Wagenpfeil J., Hölzel M., Ferring-Schmitt S., Sternberg S., Wittmann M., Peters B., Bosio A., Bieber T., Wenzel J. IL-36γ. (IL-1F9) is a biomarker for psoriasis skin lesions. J. Invest. Dermatol., 2015, Vol. 135, no. 4, pp. 1025-1032.
  10. Debets R., Timans J.C., Homey B., Zurawski S., Sana T.R., Lo S., Wagner J., Edwards G., Clifford T., Menon S., Bazar J.F. , Kastelein R.A. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol., 2001, Vol. 167, no. 3, pp. 1440-1446.
  11. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Update 2015. EDF in cooperation with EADV and IPC. Available at: http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelinesmiscellaneous [Accessed on 11 Apr 2022].
  12. Ganesan R., Raymond E.L., Mennerich D., Woska J.R., Caviness G., Grimaldi C., Ahlberg J., Perez R., Roberts S., Yang D., Jerath K., Truncali K., Frego L., Sepulveda E., Gupta P., Brown S.E., Howell M.D., Canada K.A., Kroe-Barrett R., Fine J.S., Singh S., Mbow M.L. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs, 2017, Vol. 9, no. 7, pp. 1143-1154.
  13. Matsushita T. Regulatory and effector B cells: Friends or foes? J. Dermatol. Sci., 2019, Vol. 93, no. 1, pp. 2-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Sennikova S.V., Toptygina A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies